- BSRI SMO
- /
- Medical Director
Johnette Johnson, B.S., CRA
Medical Director, BSRI SMO
Johnette Johnson is the Medical Director at Biologic-Scientific Research Institute, SMO (BSRI), and a seasoned professional in the field of clinical research. With over 23 years of experience in the industry, she has contributed to numerous clinical trials across various therapeutic areas, including oncology/hematology, rheumatology, infectious diseases, and neurology. Her background in biology, combined with her ongoing education in biochemistry, allows her to bring both scientific depth and practical insights to her role.
Prior to BSRI SMO, Johnette managed clinical trials for Icon plc, Moderna, and Pfizer, focusing on Phase I to IV trials. Her expertise in regulatory affairs and trial operations has been instrumental in driving BSRI SMO’s success. Johnette’s leadership continues to guide the organization toward achieving groundbreaking advancements in medical research and improving patient outcomes.
Johnette’s approach to clinical research is grounded in her commitment to maintaining the highest ethical standards while ensuring the safety of patients involved in studies. Her work involves close collaboration with Clinical Research Organizations (CROs), sponsors, and Institutional Review Boards (IRBs), ensuring compliance with industry standards and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH/GCP) guidelines.
Her track record in business development and project management has been instrumental in BSRI SMO’s ability to establish new research sites, increase revenue, and enhance the quality of clinical trials conducted. In 2024, the projected gross revenue from contracts with Moderna is set to exceed $2 million, showcasing the success of Johnette’s leadership and strategic direction within the organization.
Johnette Johnson leads BSRI SMO with a strong foundation in clinical operations and regulatory compliance, continually driving innovation and improving patient outcomes through rigorous oversight and ethical practices.